Datopotamab specifications, packaging and content introduction

Datopotamab deruxtecan (trade name: Datroway) is an antibody drug conjugate (ADC) targeting TROP2 and is used to treat solid tumors such as advanced or metastatic breast cancer. Its specifications and packaging are designed to ensure the stability and safety of the drug and are suitable for intravenous infusion use.

Each bottleDatopotamab deruxtecancontains100mg of freeze-dried powder, the main ingredient is Datopotamab deruxtecan-dlnk. The drug is a white to slightly yellow freeze-dried powder and contains excipients such as L-histidine, L-histidine hydrochloride, polysorbate 80 and sucrose. After reconstitution, the solution concentration is 20 mg/mL, and the pH value is approximately 6.0, which is suitable for intravenous infusion.

Datopotamab deruxtecan is packaged in single-dose bottles, each containing 100mg of the drug. The drug needs to be reconstituted and diluted before use, using sterile water for dissolution, and a 0.2 micron filter used during infusion. To ensure the stability of the drug, it is recommended to shield it from light during the infusion process and avoid mixing it with other drugs or infusing it simultaneously through the same infusion pipeline.

In terms of storage, Datopotamab deruxtecan should be stored between 2°C to 8°Cof the refrigerator, avoid freezing, and keep in the original packaging to protect it from light. Before use, drugs should be reconstituted and diluted in a sterile environment to ensure their quality and safety.

In short, the specifications and packaging design of Datopotamab deruxtecan fully consider the stability and infusion safety of the drug to ensure the safety of patients during the treatment process. During use, medical personnel should strictly follow the instructions to ensure treatment effects and patient safety.

Reference materials:https://www.drugs.com/